Magenta Q2 net loss $17.3M; cash $139.4M; MGTA-117 interim data expected Q4 2022

Dianthus Therapeutics, Inc. /DE/

2022-Q2 EPS reported -$0.68

Cash, equivalents, and marketable securities $139.4M as of June 30, 2022; funds operations into Q2 2024.
Net loss of $17.3M in Q2 2022 vs. $16.9M in Q2 2021; R&D expenses $11.6M, G&A $6.5M.
MGTA-117 Phase 1/2 trial progressing; interim clinical data from multiple dose cohorts on track for Q4 2022.
CD45-ADC IND-enabling studies ongoing; in-life toxicology complete; program update expected Q4 2022.
MGTA-145 stem cell mobilization trial in sickle cell disease initiated; initial data anticipated Q4 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.